Bayer secures approval in the EU for Xarelto ® (rivaroxaban) for patients with coronary or peripheral artery disease (for specialized target groups only)

Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germany
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news